WallStSmart
SANA

Sana Biotechnology Inc

NASDAQ: SANA · HEALTHCARE · BIOTECHNOLOGY

$3.56
-9.46% today

Updated 2026-06-05

Market cap
$745.82M
P/E ratio
P/S ratio
EPS (TTM)
$-0.92
Dividend yield
52W range
$3 – $7
Volume
3.8M

Sana Biotechnology Inc (SANA) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20182019202020212022202320242025
Operating cash flow$-13.49M$-85.50M$-137.98M$-251.05M$-290.05M$-253.58M$-223.15M$-143.83M
Capital expenditures$460000.00$26.18M$23.87M$29.86M$20.88M$20.03M$33.43M$938000.00
Depreciation
Stock-based comp$118000.00$1.50M$5.83M$22.36M$38.34M$35.53M$37.68M$25.46M
Free cash flow$-13.96M$-111.69M$-161.85M$-280.92M$-310.93M$-273.61M$-256.58M$-144.77M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash$134.90M$-74.58M

Frequently asked questions

How much free cash flow does SANA generate?

SANA produced $-144.77M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is SANA's balance sheet healthy?

SANA holds $71.87M in cash and equivalents against — in long-term debt, on $160.88M of shareholder equity. That debt is best read against the cash flow the business throws off each year.